Literature DB >> 34388478

Propofol induces hepatocellular carcinoma cell apoptosis via regulating miR-105/JAK2/STAT3 axis.

Jingjin Li1, Mengjiang Liu1, Bin Zeng1, Zhonghai Wang2.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is a type of malignancy with high mortality. It has been reported Propofol could modulate the tumorigenesis of liver cancer; however, the mechanism by which Propofol regulates the development of HCC is still not clear.
METHODS: CCK8 assay was applied to test the cell viability. Flow cytometry and TUNEL staining were applied to detect the cell apoptosis. Meanwhile, dual luciferase reporter assay was performed to investigate the association between miR-105 and JAK2. In addition, RNA and protein levels were investigated by qRT-PCR and western blot, respectively.
RESULTS: Propofol significantly suppressed the proliferation of HCC cells via inducing the apoptosis. Consistently, miR-105 upregulation inhibited the proliferation of HCC cells, while downregulation of miR-105 reversed Propofol-induced HCC cell apoptosis. Meanwhile, JAK2 was found to be the direct target of miR-105. Furthermore, Propofol could inactivate JAK2/STAT3 signaling via upregulation of miR-105.
CONCLUSION: Propofol significantly attenuated HCC tumorigenesis via mediation of miR-105/JAK2/STAT3 axis. Thereby, Propofol might act as a new agent for the treatment of HCC.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HCC; JAK2/STAT3 signaling; Propofol; miR-105

Mesh:

Substances:

Year:  2021        PMID: 34388478     DOI: 10.1016/j.cyto.2021.155649

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  2 in total

1.  Propofol suppresses adipose-derived stem cell progression via PI3K/AKT-Wnt signaling pathway.

Authors:  Guoping Yin; Jia Wang; Yanling Zhong; Weidong Wu
Journal:  BMC Anesthesiol       Date:  2022-03-09       Impact factor: 2.217

2.  Propofol Augments Paclitaxel-Induced Cervical Cancer Cell Ferroptosis In Vitro.

Authors:  Meng-Yun Zhao; Pan Liu; Chen Sun; Li-Jian Pei; Yu-Guang Huang
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.